The influence of toxicity constraints in models of chemotherapeutic protocol escalation
KAUST Grant NumberKUK-C1-013-04
Online Publication Date2011-04-06
Print Publication Date2011-12-01
Permanent link to this recordhttp://hdl.handle.net/10754/599924
MetadataShow full item record
AbstractThe prospect of exploiting mathematical and computational models to gain insight into the influence of scheduling on cancer chemotherapeutic effectiveness is increasingly being considered. However, the question of whether such models are robust to the inclusion of additional tumour biology is relatively unexplored. In this paper, we consider a common strategy for improving protocol scheduling that has foundations in mathematical modelling, namely the concept of dose densification, whereby rest phases between drug administrations are reduced. To maintain a manageable scope in our studies, we focus on a single cell cycle phase-specific agent with uncomplicated pharmacokinetics, as motivated by 5-Fluorouracil-based adjuvant treatments of liver micrometastases. In particular, we explore predictions of the effectiveness of dose densification and other escalations of the protocol scheduling when the influence of toxicity constraints, cell cycle phase specificity and the evolution of drug resistance are all represented within the modelling. For our specific focus, we observe that the cell cycle and toxicity should not simply be neglected in modelling studies. Our explorations also reveal the prediction that dose densification is often, but not universally, effective. Furthermore, adjustments in the duration of drug administrations are predicted to be important, especially when dose densification in isolation does not yield improvements in protocol outcomes. © The author 2011. Published by Oxford University Press on behalf of the Institute of Mathematics and its Applications. All rights reserved.
CitationBoston EAJ, Gaffney EA (2011) The influence of toxicity constraints in models of chemotherapeutic protocol escalation. Mathematical Medicine and Biology 28: 357–384. Available: http://dx.doi.org/10.1093/imammb/dqr004.
SponsorsThis publication is based on work supported in part by Award No. KUK-C1-013-04, made by King Abdullah University of Science and Technology (KAUST). It was also supported in part by the Engineering and Physical Sciences Research Council, UK (EPSRC GR/S72023/01).
PublisherOxford University Press (OUP)
CollectionsPublications Acknowledging KAUST Support
- The mathematical modelling of adjuvant chemotherapy scheduling: incorporating the effects of protocol rest phases and pharmacokinetics.
- Authors: Gaffney EA
- Issue date: 2005 May
- Modelling chemotherapy resistance in palliation and failed cure.
- Authors: Monro HC, Gaffney EA
- Issue date: 2009 Mar 21
- Chemotherapy of metastatic bowel cancer.
- Authors: Ross PJ, Cunningham D
- Issue date: 1996 Mar 6-19
- Cell cycle-mediated drug resistance: an emerging concept in cancer therapy.
- Authors: Shah MA, Schwartz GK
- Issue date: 2001 Aug
- Neoadjuvant treatment with weekly high-dose 5-fluorouracil as a 24h-infusion, folinic acid and biweekly oxaliplatin in patients with primary resectable liver metastases of colorectal cancer: long-term results of a phase II trial.
- Authors: Boxberger F, Albrecht H, Konturek PC, Reulbach U, Maennlein G, Meyer T, Hohenberger W, Hahn EG, Wein A
- Issue date: 2010 Feb